Oncolytic viral therapy for solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase I/II study evaluates the safety and efficacy of OH2, an oncolytic virus derived from herpes simplex virus type 2, in patients with malignant solid tumors, including gastrointestinal cancers. The trial consists of a dose escalation phase to determine the maximum tolerated dose (MTD) and a dose expansion phase with four treatment cohorts, some receiving OH2 in combination with other therapies like HX008 and irinotecan. The study also assesses the biodistribution of the virus and monitors adverse events using established criteria.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Histologically or cytologically confirmed unresectable or recurrent/metastatic solid tumors.
2. The patient must have failed the standard treatment (due to either disease progression or intolerable toxicity) or the standard of care had not been established for the specific condition.
3. Measurable disease based on Response Evaluation Criteria In Solid Tumors (RECIST) 1.1.
4. Eastern Collaborative Oncology Group (ECOG) Performance Status ≤ 1.
5. Life expectancy \>3 months.
6. The patient must have at least one tumor site appropriate for intratumoral injection.
7. Adequate organ function.
8. Participants of reproductive potential must be willing to use adequate contraception for the course of the study until 3 months after the last dose of any of the drugs in the study.
9. Participants with a history of HSV infection must have recovered at least 3 months before the study.
10. Willing and able to provide written informed consent and comply with the requirements of the study.

Exclusion Criteria:

1. Uncontrolled concurrent illness including, but not limited to, severe cardiac disease, cerebralvascular disease, uncontrolled diabetes, uncontrolled hypertension, ongoing or active systemic infection, active peptic ulcer disease.
2. Central nervous system (CNS) metastases with clinical symptoms
3. Active infection or an unexplained fever \> 38.5°C.
4. Known Human Immunodeficiency Virus (HIV) infection, active Hepatitis B or Hepatitis C infection.
5. Pregnant or lactating female.
6. Patients who are receiving any other investigational agents.
7. Known immediate or delayed hypersensitivity reaction to HSV.
8. Previous malignancy within 5 years prior to study entry.
9. Patients with any active autoimmune disease or history of autoimmune disease.
10. Concurrent medical condition requiring the use of cortisol (\>10mg/day prednisone or equivalent dose) or other systematic immunosuppressive medications within 14 days before the study treatment, except for inhalation or topical corticosteroids no more than 10 mg/day prednisone or equivalent.
11. Familial, sociological or geographical conditions that, in the judgment of the investigator, do not permit compliance with the protocol.

Where it's running

• National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: Jing Huang, MD
• Email: huangjingwg@163.com
• Phone: 8610-87788102

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Injecting engineered immune cells to treat advanced solid tumors

  This study is testing a new treatment that uses specially modified immune cells taken from patients' tumors to see if it can help people with advanced cancers that haven't responded to other treatments.

  Recruiting Phase 1 Shanghai Juncell Therapeutics · Shanghai · NCT06375187

• Personalised azacitidine combination therapy using AI-guided drug selection and dosing

  This study tests whether AI tools can pick the best azacitidine drug combination and personalise dosing for adults with certain solid tumours using each person's biopsy sample.

  Recruiting Phase 1/2 National University Hospital, Singapore · Singapore · NCT05381038

• SumMET: Targeted radioligand therapy for c-MET–positive solid tumors

  This first‑in‑human study tests the safety and potential effectiveness of a radioligand therapy called [225Ac]Ac-FL-261 in adults with advanced or metastatic solid tumors that overexpress c-MET.

  Recruiting at 2 sites Phase 1/2 Full-Life Technologies UK Limited · Minneapolis, Minnesota and 1 other locations · NCT07873450

• SHR-4595 Injection in Advanced Solid Tumors: Safety, Tolerability, and Dosing in Phase 1

  This early-phase trial tests SHR-4595 injections to see if they are safe and tolerable for adults with advanced solid tumors who have exhausted standard treatments.

  Recruiting at 2 sites Phase 1 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Shenyang, Liaoning and 1 other locations · NCT07830199

• Frailty before GI cancer surgery: does frailty predict post-op outcomes in older adults?

  This study tests whether frailty measured before surgery can predict complications and recovery in patients 60 and older undergoing elective gastrointestinal cancer surgery.

  Recruiting Van Training and Research Hospital · Van, Van · NCT07815392

• Biological Collection to Help Create Models for Digestive Cancers and IBD

  Researchers are gathering tissue and biological samples from patients with inflammatory bowel disease or digestive cancers to build personalized models and test new therapies.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07782203

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.